VCTX-211

N/A

Report date: 2026/05/08 20:02:52

Base Information

Drug NameVCTX-211
Drug Alias NameVCTX-211CTX-211
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Somatic cell > Pancreatic endoderm cell therapy
Mechanisms of ActionStem cell replacementsR7V inhibitorsMesencephalic astrocyte-derived neurotrophic factor modulators
TargetsBeta-2-microglobulinMesencephalic astrocyte-derived neurotrophic factor
Therapy Area/IndicationsAutoimmune DiseasesImmune System DiseasesEndocrine System Diseases +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaSwitzerland
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaN/A
Originator CompaniesCrispr Therapeutics AgViacyte Inc
China Registration ClassN/A

Develop Information

Active CompaniesViacyte IncCrispr Therapeutics Ag
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsAutoimmune DiseasesImmune System DiseasesEndocrine System Diseases +[6] 

Other Information

ATC CodeN/A
Related LinksN/A